Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Whitehawk Therapeutics (WHWK) Return on Capital Employed: 2019-2025

Historic Return on Capital Employed for Whitehawk Therapeutics (WHWK) over the last 6 years, with Sep 2025 value amounting to -0.66%.

  • Whitehawk Therapeutics' Return on Capital Employed rose 19.00% to -0.66% in Q3 2025 from the same period last year, while for Sep 2025 it was -0.66%, marking a year-over-year increase of 19.00%. This contributed to the annual value of -0.80% for FY2024, which is 26.00% down from last year.
  • Whitehawk Therapeutics' Return on Capital Employed amounted to -0.66% in Q3 2025, which was down 28.34% from -0.52% recorded in Q2 2025.
  • In the past 5 years, Whitehawk Therapeutics' Return on Capital Employed registered a high of -0.06% during Q2 2021, and its lowest value of -1.11% during Q4 2024.
  • Over the past 3 years, Whitehawk Therapeutics' median Return on Capital Employed value was -0.66% (recorded in 2023), while the average stood at -0.66%.
  • Its Return on Capital Employed has fluctuated over the past 5 years, first tumbled by 104bps in 2022, then spiked by 65bps in 2023.
  • Whitehawk Therapeutics' Return on Capital Employed (Quarterly) stood at -0.75% in 2021, then spiked by 38bps to -0.37% in 2022, then dropped by 29bps to -0.66% in 2023, then slumped by 45bps to -1.11% in 2024, then rose by 19bps to -0.66% in 2025.
  • Its Return on Capital Employed stands at -0.66% for Q3 2025, versus -0.52% for Q2 2025 and -0.45% for Q1 2025.